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Abstract 27 
Ghrelin is a multifunctional hormone, with roles in stimulating appetite and regulating energy balance, 28 
insulin secretion and glucose homeostasis. The ghrelin gene locus (GHRL) is highly complex and 29 
gives rise to a range of novel transcripts derived from alternative first exons and internally spliced 30 
exons. The wild-type transcript encodes a 117 amino acid preprohormone that is processed to yield 31 
the 28 amino acid peptide ghrelin. Here, we identified insulin-responsive transcription corresponding 32 
to cryptic exons in intron 2 of the human ghrelin gene. A transcript, termed in2c-ghrelin (intron 2-33 
cryptic), was cloned from the testis and the LNCaP prostate cancer cell line. This transcript may 34 
encode an 83 AA preproghrelin isoform that codes for the ghrelin, but not obestatin. It is expressed in 35 
a limited number of normal tissues and in tumours of the prostate, testis, breast and ovary. Finally, we 36 
confirmed that in2c-ghrelin transcript expression, as well as the recently described in1-ghrelin 37 
transcript, is significantly upregulated by insulin in cultured prostate cancer cells. Metabolic 38 
syndrome and hyperinsulinaemia has been associated with prostate cancer risk and progression. This 39 
may be particularly significant after androgen deprivation therapy for prostate cancer, which induces 40 
hyperinsulinaemia, and this could contribute to castrate resistant prostate cancer growth. We have 41 
previously demonstrated that ghrelin stimulates prostate cancer cell line proliferation in vitro. This 42 
study is the first description of insulin regulation of a ghrelin transcript in cancer, and should provide 43 
further impetus for studies into the expression, regulation and function of ghrelin gene products. 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
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Introduction 54 
The 28 amino acid hormone, ghrelin, has emerged as a multifunctional peptide hormone with actions 55 
beyond its roles in growth hormone secretion, appetite regulation and energy balance (Kojima et al. 56 
1999; Lim et al. 2011; Nakazato et al. 2001; Wren et al. 2000). In addition to its role in normal 57 
physiology, ghrelin has been associated with a number of disease processes, including obesity (Scerif 58 
et al. 2011; Yi et al. 2011), type 2 diabetes mellitus and hyperinsulinaemia (Ukkola 2011), 59 
gastrointestinal disease (Jeffery et al. 2011), cardiovascular disease (Isgaard and Granata 2011), 60 
reproductive disorders (Repaci et al. 2011), mental health (Steiger et al. 2011) and cancer (Chopin et 61 
al. 2011; Deboer 2011). Ghrelin may play a role in prostate cancer progression, and we have 62 
previously demonstrated that ghrelin mRNA and protein is expressed in prostate cancer cell lines and 63 
tissues and that ghrelin stimulates cell proliferation in prostate cancer cell lines (Jeffery et al. 2002; 64 
Yeh et al. 2005).  65 
 66 
The ghrelin gene consists of four preproghrelin-coding exons (exons 1 to 4) that give rise to a 117 67 
amino acid preproghrelin peptide (Kojima et al. 1999; Seim et al. 2011b). The first 23 amino acids are 68 
encoded by exon 1 and harbour a secretory signal peptide, while the remainder of exon 1 and part of 69 
exon 2 encode the 28 amino acid ghrelin peptide. Exon 3 encodes obestatin, a recently-discovered 23 70 
amino acid peptide hormone with a range of novel functions, including regulation of adipogenesis, 71 
insulin secretion and pancreatic homeostasis and cancer cell progression (Seim et al. 2011b; Zhang et 72 
al. 2005).  73 
 74 
Following cleavage of the signal peptide, the 94 amino acid proghrelin peptide is post-translationally 75 
modified in the endoplasmic reticulum where an octanoyl fatty acid group (acyl group) is added to the 76 
third residue of ghrelin, a serine, by the recently discovered enzyme ghrelin O-acyl transferase/GOAT 77 
(Gutierrez et al. 2008; Yang et al. 2008). Although both ghrelin and desacyl ghrelin circulate in the 78 
blood, the levels of desacyl ghrelin are significantly higher (Date et al. 2000; Holmes et al. 2009; 79 
Patterson et al. 2005).  This may be the result of the rapid conversion of ghrelin to desacyl ghrelin by 80 
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esterases in the circulation (Beaumont et al. 2003; De Vriese et al. 2004; Eubanks et al. 2011; Satou 81 
et al. 2010). Alternatively desacyl ghrelin may be produced from proghrelin in the absence of GOAT 82 
expression, or when the fatty acid substrates for GOAT are unavailable (Takahashi et al. 2009). Only 83 
the acylated form of ghrelin is able to bind the cognate receptor, the growth hormone secretagogue 84 
receptor type 1a (GHSR1a) (Howard et al. 1996; Kojima et al. 1999), although alternative receptors 85 
for both acylated and desacyl ghrelin must also exist (Seim et al. 2011a). It has been demonstrated 86 
that GOAT and ghrelin play a crucial role in glucose balance , particularly in response to caloric 87 
restriction (Zhao et al. 2010), however, this finding has not been replicated in a number of mouse 88 
models (Yi et al. 2012). While the role of the ghrelin axis in insulin and glucose balance is currently 89 
unclear, ghrelin and GOAT may be useful therapeutic targets for treating insulin resistance (Kirchner 90 
et al. 2010; Lim et al. 2011; Romero et al. 2010). Insulin resistance is also common in prostate cancer 91 
patients after androgen deprivation therapy (Aggarwal et al. 2011).  92 
 93 
It is now well established that the majority of genes generate alternative splice forms, many of which 94 
have novel functions (Nilsen and Graveley 2010). This is particularly true for preprohormones, which 95 
frequently harbour a range of bioactive peptides. The ghrelin gene (GHRL) is no exception, and it is 96 
now realised that the ghrelin locus encodes multiple bioactive molecules derived by alternative 97 
transcriptional splicing, proteolytic cleavage of larger precursor peptides and by other post-98 
translational modifications (Seim et al. 2009; Seim et al. 2011a). 99 
 100 
Here, we report a novel preproghrelin splice variant, termed in2c-ghrelin (intron 2-cryptic) that 101 
contains novel exon sequence derived from intron 2 of the ghrelin gene and investigate its expression 102 
in cancer. We demonstrate that this novel transcript, as well as the recently described in1-ghrelin 103 
transcript (Gahete et al. 2011; Gahete et al. 2010; Kineman et al. 2007), are upregulated in response 104 
to insulin treatment in the 22Rv1 and LNCaP prostate cancer cell lines and, therefore, they may have 105 
a role in prostate cancer progression, particularly in cases of hyperinsulinaemia. 106 
 107 
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Materials and Methods 108 
 109 
Cell Culture 110 
Cell lines were originally obtained from the American Type Culture Collection (ATCC, Rockville, 111 
MD). The PC3 (ATCC CRL-1435), DU145 (ATCC HTB-81), LNCaP (ATCC CRL-1740) and 22Rv1 112 
(ATCC CRL-2505) prostate cancer cell lines were maintained in Roswell Park Memorial Institute 113 
(RPMI) 1640 medium (Invitrogen, Carlsbad, CA) with 10% New Zealand Cosmic Calf Serum (FCS, 114 
HyClone, South Logan, UT) supplemented with 100 U/mL penicillin G and 100 µg/mL streptomycin 115 
(Invitrogen). All cell lines were passaged at two to three day intervals at 70% confluency using 0.25% 116 
Trypsin/EDTA (380 mg/ml or 0.913 mM EDTA, and 2500 mg/ml or 0.105 mM trypsin) (Invitrogen). 117 
Cell morphology and viability was monitored by microscopic observation and regular testing was 118 
performed by PCR (Universal Mycoplasma Detection Kit, ATCC) to ensure that cells were not 119 
contaminated with Mycoplasma.  120 
 121 
Microarray profiling of insulin-treated LNCaP prostate cancer cell line 122 
To identify RNAs expressed in the prostate that could be developed as disease-specific targets for 123 
prostate cancer treatment, we employed a custom-designed microarray from the Vancouver Prostate 124 
Centre (VPC). The microarray, an Agilent custom 2x105K array (Agilent Technologies, Wilmington, 125 
DE), combines the probes from the Agilent 44K (v1) human gene expression set with probes targeting 126 
alternative protein isoforms and non-coding RNAs.  All probes on the microarray were classified 127 
based on their relationship to the RNAs in the NCBI RefSeq database 128 
(http://www.ncbi.nlm.nih.gov/RefSeq; December 2010).  129 
 130 
LNCaP prostate cancer cells were seeded on 10 cm tissue culture flasks (Nunc, International) in 131 
phenol-red free RPMI1640 medium with 5% FCS (Invitrogen) and left overnight to attach. The 132 
following day, serum was replaced with 5% charcoal-stripped serum (Invitrogen) for 48 hours, 133 
followed by a 24 hour incubation in serum-free medium and treatment with 10 nM insulin (Sigma-134 
Page 5 of 38
6 
 
Aldrich, St. Louis, MO) or an equal volume of vehicle (70% ethanol) for 10 hours. All treatments 135 
were performed in triplicate. Total RNA was isolated using TRIzol (Invitrogen), One-colour gene 136 
expression analysis was performed following Agilent labeling (Quick Amp Labeling Kit), 137 
hybridisation, and scanning (Agilent Feature Extraction version 10.5.1) protocols using the custom 138 
Agilent 2x105K microarray. Data were normalised using the quantile normalisation method in Linear 139 
Models for Microarray Data (LIMMA), an open-source R-based software package for the analysis of 140 
gene expression data (Smyth 2005). Differential gene expression was determined using LIMMA 141 
linear models with an FDR adjusted p-value ≤ 0.05 and fold change ≥ 1.5. 142 
  143 
In silico and RT-PCR verification of putative ghrelin exons identified by microarray analysis 144 
To investigate whether novel exons identified by microarray analysis correspond to splice variants of 145 
the preproghrelin gene (GHRL), and to determine the open reading frame of any resulting full-length 146 
transcript, we performed BLAST queries (Johnson et al. 2008), UCSC Genome Browser multigenome 147 
alignments (specifically, the 17-way conservation track) (Fujita et al. 2011), and RT-PCR with 148 
primers spanning the putative exons (In2c-ghrelin-ORF-F/R, Table 1). Briefly, for RT-PCR analyses 149 
2 µg total RNA from human testis and pancreas (FirstChoice, Ambion, Austin, TX), and from the 150 
LNCaP prostate cancer cell line were subjected to DNase I digestion (amplification grade, Invitrogen), 151 
and cDNA synthesis with SuperScript III and oligo(dT)18 primers (Invitrogen) according to the 152 
manufacturer's instructions. RT-PCR was performed in a total reaction volume of 50 µl containing 1 × 153 
PCR buffer, 0.2 mM deoxynucleotide triphosphates, 1.5 mM MgCl2, 0.2 µM primers (In2c-ghrelin-154 
ORF-F/R, Table 1), 1 µl cDNA and 1 unit of Platinum Taq DNA Polymerase (Invitrogen) on a PTC-155 
200 thermal cycler (MJ Research, Watertown, MA) according to the manufacturer's instructions. 156 
Negative, no-template controls were performed.  157 
 158 
Quantitative real time RT-PCR of cultured cells and tissues 159 
Unless otherwise noted, total RNA was harvested from cultured cells using QIAshredder and RNEasy 160 
Plus Mini kits (QIAGEN, Australia), according to the manufacturer's instructions, and stored frozen at 161 
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-80°C. RNA concentration and purity were measured using a NanoDrop ND-1000 spectrophotometer 162 
(Thermo Fisher Scientific, Australia) to ensure adequate RNA quality. Contaminating genomic DNA 163 
was removed by DNase I digestion (amplification grade, Invitrogen), and 2 µg total RNA was reverse 164 
transcribed with oligo(dT)18 primers using SuperScript III (Invitrogen). The prostate cancer cell lines 165 
described above, as well as RNA previously isolated from cell lines derived from normal lung (Beas-166 
2B, ATCC CRL-9609), non-small cell lung cancer (A549, ATCC CCL-185 and NCI-H1299, ATCC 167 
CRL-5803), normal ovary (hOSE17.1), ovarian cancer (SKOV-3, ATCC HTB77) and breast cancer 168 
(MDA-MB231, ATCC HTB-26) were examined. Quantitative real-time RT-PCR was performed 169 
using primers In2c-real-F/R (Table 1) with 2 × SYBR green master mix (Applied Biosystems; AB, 170 
Foster City, CA) on a PRISM 7000 Sequence-Detection System (AB). Data were analysed using the 171 
comparative 2
-∆∆Ct
 method (Livak and Schmittgen 2001). Expression in different samples is shown as 172 
fold change (relative values) compared to a calibrator sample (value denoted as 1) after normalisation 173 
to the 18S ribosomal RNA housekeeping gene. Primers are shown in Table 1. 174 
 175 
Normal human tissue (HMRT102) and cancer (CSRT103) cDNA panels were purchased from 176 
OriGene (Rockville, MD). HMRT102 consists of 48 normal tissues (adrenal gland, bone marrow, 177 
brain, breast, cervix, colon, duodenum, epididymis, fat, heart, small intestine, intracranial artery, 178 
kidney, liver, lung, lymph node, peripheral blood leukocytes, muscle, nasal mucosa, oesophagus, 179 
optic nerve, ovary, oviduct, pancreas, penis, pericardium, pituitary, placenta, prostate, rectum, retina, 180 
seminal vesicles, skin, spinal cord, spleen, stomach, testis, thymus, thyroid, tongue, tonsil, trachea, 181 
urethra, urinary bladder, uterus, uvula, vagina, and vena cava), while CSRT103 consists of 2-6 normal 182 
and approximately 20 tumour samples from a range of tissues. In2c-ghrelin was interrogated as 183 
detailed above using the AB PRISM 7000 Sequence Detection System  in a total reaction volume of 184 
20 µl using 2× SYBR green master mix (AB) on separate, identical array plates, which were loaded 185 
with equal amounts of cDNA per well.  186 
 187 
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Quantitative real time RT-PCR analysis of the effect of insulin on in2c-ghrelin and in1-ghrelin 188 
expression in cultured prostate cancer cells 189 
In order to verify the microarray data, which indicated that the novel in2c-ghrelin transcript is 190 
upregulated by insulin, we performed qRT-PCR on RNA extracted from the LNCaP and 22Rv1 191 
prostate cancer cell lines. The LNCaP and 22Rv1 prostate cancer cell lines were cultured in six-well 192 
plates in phenol red-free RPMI 1640 (Invitrogen), as outlined above, except that cells were treated 193 
with 10 nM insulin (Sigma-Aldrich) for 48 hours. Insulin was refreshed after 24 hours. RNA 194 
extractions and qRT-PCR were performed as outlined above. In1-ghrelin (In1-real-F/R, Table 1) and 195 
wild-type ghrelin (wt-real-F/R, Table 1) were detected using primer sequences published by Gahete 196 
and colleagues (Gahete et al. 2011; Gahete et al. 2010). All treatments were performed in triplicate. 197 
Data was analysed using the comparative 2
-∆∆Ct
 method (Livak and Schmittgen 2001). Ribosomal 198 
protein, L32 (RPL32F/R, Table 1), which is particularly suitable for cultured prostate cancer cells 199 
(Lubik et al. 2011), was employed as a housekeeping gene for qRT-PCRs. 200 
 201 
RT-PCR product purification and sequencing 202 
All RT-PCR products were, unless noted, purified using a MinElute (QIAGEN) PCR Purification Kit, 203 
cloned into pGEM-T Easy (Promega, Madison, WI), transformed into One Shot MAX Efficiency 204 
DH5α-T1R chemically-competent cells (Invitrogen) and sequenced at the Australian Genome 205 
Research Facility (AGRF, Brisbane, Australia) using BigDye III (Applied Biosystems). 206 
 207 
Statistical analyses 208 
Data are expressed as means ± standard deviation. Statistical significance was determined using 209 
Student’s t-test using Graphpad Prism (La Jolla, CA) or Microsoft Excel (Seattle, WA) software with 210 
a P value <0.05 considered to be statistically significant.  211 
 212 
Results  213 
 214 
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Identification and cloning of novel, cryptic exons of the ghrelin gene (GHRL) 215 
Using human exon-junction microarray probes, novel exons (named I and II) located in intron 2 of 216 
GHRL were found to be upregulated 3.9-fold by treatment with 10 nM insulin in the LNCaP prostate 217 
cancer cell line (Figure 1). These exons match four GenBank entries (EF139854-57) that partially 218 
overlap the ghrelin coding-exons and contain novel exon sequence in intron 2 (Figure 2). 219 
Interestingly, the GenBank entries are previously unpublished RT-PCR validations of testis-specific 220 
exons which were identified in a large-scale study by Clark and colleagues (Clark et al. 2007). Their 221 
study employed exon arrays to locate tissue-specific exons in 16 normal tissues, but focused on novel, 222 
brain-enriched exons in the published manuscript (Clark et al. 2007). To verify whether the novel 223 
exons correspond to splice variants of the ghrelin gene and to determine the open reading frame of 224 
these transcripts, RT-PCRs were performed (using cDNA reverse transcribed with oligo(dT)18 225 
primers) using RNA from the LNCaP prostate cancer cell line, human testis and pancreas (with a 226 
forward primer in exon 1 of ghrelin and a reverse primer in the novel exon II, which is common to all 227 
of the testis-derived GenBank entries). A single, major amplicon was obtained in the testis and 228 
LNCaP cell line, representing exons 1, 2 and II of GHRL (Figure 1; Supplementary Figure 1) 229 
(GenBank: JN243773). We have termed the identified full-length splice variant in2c-ghrelin (intron 2 230 
cryptic-ghrelin). The exons for In2c-ghrelin have canonical GT/AG splice junctions, with the 231 
exception of the intron flanking a 5’ truncated exon II, exon IIb, which harbours a rare GT/AC 232 
junction (Burset et al. 2000) (Figure 2). The cryptic exons in the human gene are not conserved in the 233 
mouse or rat, which would, therefore, be unlikely to express the in2c-ghrelin isoform (data not 234 
shown). These analyses demonstrate that the human GHRL gene contains additional exons within 235 
intron 2 that are bona fide internal exons of preproghrelin splice variants that harbour exons 1, 2, 3 236 
and 4. 237 
 238 
The novel In2c-ghrelin isoform includes  cryptic exons that lead to a frameshift in the translation of 239 
preproghrelin. The 83 amino acid in2c-ghrelin isoform harbours the coding region for the 28 amino 240 
acid mature ghrelin peptide (Figure 3). While the C-terminal (C-ghrelin) region of wild-type ghrelin 241 
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encodes a 66 amino acid peptide, the open reading frame of in2c-ghrelin encodes  the first 24 amino 242 
acids of the C-ghrelin sequence and 8 unique C-terminal residues, before the introduction of a stop 243 
codon. As a result of the frameshift, it lacks the coding sequence for obestatin (Figure 3). The 3’ 244 
untranslated region of the mRNA is otherwise identical to wild-type ghrelin, and has the same 245 
polyadenylation signal.  246 
 247 
Quantification of in2c-ghrelin in normal tissues 248 
To selectively amplify the in2c-variant and to avoid co-amplification of ghrelin pre-mRNA or 249 
genomic DNA, we designed a reverse qRT-PCR primer that spans the exon II-exon 3 junction 250 
(Supplementary Figure 2). Quantitative real-time RT-PCR analyses of 48 tissues show that in2c-251 
ghrelin mRNA, in contrast to the wild-type ghrelin transcript (Gnanapavan et al. 2002; Ueberberg et 252 
al. 2009), is expressed in a small number of tissues, including the stomach, lymph node, peripheral 253 
blood leukocytes, testis, epididymis, skin and adrenal gland (Figure 4). 254 
 255 
Quantification of in2c-ghrelin in cell lines 256 
Next, we examined the expression of in2c-ghrelin in cultured cells using qRT-PCR. In2c-ghrelin was 257 
highly expressed in the PC3, LNCaP and 22Rv1 prostate cancer cell lines, while the DU145 prostate 258 
cancer cell line did not express this transcript (Figure 5). In2c-ghrelin expression was low in the lung, 259 
ovarian and breast cell lines examined. Interestingly, in2c-ghrelin is expressed in the SKOV-3 ovarian 260 
cancer cell line, but not in the hOSE1.7 normal ovarian cell line (Figure 5). 261 
 262 
In2c-ghrelin expression in normal versus tumour samples 263 
To further explore the role of in2c-ghrelin in cancer, we analysed the expression of the variant using 264 
commercial cDNA arrays from OriGene. In the testis cDNA tissue panel, in2c-ghrelin was expressed 265 
in normal testicular tissue, but is absent or present at low levels in testicular tumour samples (Figure 266 
6A). Conversely, prostate tumours exhibited high levels of in2c-ghrelin compared to normal prostate 267 
tissue (with 9/19 expressing higher levels than normal tissue, and 14/19 prostate tumours expressing 268 
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the variant) (Figure 6B). Finally, normal breast (Figure 6C) and ovary (Figure 6D) samples did not 269 
express in2c-ghrelin, while the transcript was expressed in 13/20 breast tumours and 7/21 ovarian 270 
tumours examined. Together, these results demonstrate that in2c-ghrelin is expressed at high levels in 271 
prostate cancer cell lines and prostate tumour tissue. It is expressed in all normal testis samples 272 
examined, while its expression is low or absent in testicular tumours; and it is expressed in breast and 273 
ovarian tumour, but not normal tissue. 274 
 275 
In2c-ghrelin expression is regulated by insulin in prostate cancer cells 276 
The microarray experiment revealed that in2c-ghrelin was regulated by insulin in LNCaP prostate 277 
cancer cells, therefore, we confirmed that this transcript is insulin regulated using quantitative RT-278 
PCR of the LNCaP and 22Rv1 prostate cancer cell lines. As shown in Figure 7A, treatment with 10 279 
nM insulin significantly increased the expression of in2c-ghrelin in the LNCaP (1.3 fold, P<0.05) and 280 
22Rv1 (4.4-fold, P<0.05) prostate cancer cell lines. Interestingly, insulin also significantly 281 
upregulated the expression of a recently-reported intron 1-retained transcript, in1-ghrelin (Gahete et 282 
al. 2011; Gahete et al. 2010; Kineman et al. 2007). A 2.2-fold increase in expression was observed in 283 
LNCaP cells and a 2.8 fold increase in 22Rv1 cells (Figure 7B). 284 
 285 
Discussion 286 
We have demonstrated a new ghrelin isoform that is regulated by insulin treatment in prostate cancer 287 
cell lines. Cryptic exon sequence in the in2c-ghrelin variant leads to a frame-shift in the translation of 288 
preproghrelin and leads to an open reading frame that would encode an 83 amino acid preproghrelin 289 
peptide, which is considerably shorter than the 117 amino acid wild-type form. This isoform contains 290 
the 28 amino acid ghrelin, but lacks the coding sequence for obestatin. 291 
 292 
This study provides further evidence that microarrays, and in particular exon arrays where probes are 293 
designed to detect individual exons, are excellent tools to discover novel alternative exons (Clark et 294 
al. 2007; French et al. 2007; Menghi et al. 2011; Rahman et al. 2010; Skotheim and Nees 2007). The 295 
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exon-junction probe in our custom array was designed to target GenBank sequences deposited by 296 
Affymetrix as a result of RT-PCR validation of testis-enriched exon array data (Clark et al. 2007). 297 
Alternative splicing results in cell- or tissue-specific expression of exons, and is frequently observed 298 
in cancer (He et al. 2009; Nilsen and Graveley 2010; Skotheim and Nees 2007).  299 
 300 
We have previously demonstrated that ghrelin mRNA and protein is expressed in prostate cancer cell 301 
lines, using RT-PCR and Western blotting (Jeffery et al., 2002; Yeh et al., 2005). Expression of the 302 
ghrelin peptide has been demonstrated in prostate cancer cell lines using Western analysis and in 303 
clinical specimens of prostate cancer using immunohistochemistry. Using these methods, it is not 304 
possible to discriminate between the expression of wild-type ghrelin and the in2c ghrelin peptide 305 
isoforms at the peptide level. The in2c-ghrelin mRNA isoform appears to be particularly highly 306 
expressed in prostate cancer cell lines and tissues, but is expressed at low levels or is absent in normal 307 
prostate tissue, which may indicate that the variant could be a useful diagnostic or prognostic marker 308 
for this cancer. A recent in vitro binding study using a fluorescein labelled ghrelin-derived probe 309 
(consisting of the first 18 amino acids of ghrelin) has demonstrated that ghrelin may have potential as 310 
a diagnostic or prognostic marker for prostate cancer (Lu et al. 2012). Ghrelin binding was 311 
significantly higher in clinical samples of prostate cancer compared to normal tissue and samples of 312 
benign prostate hyperplasia in a study with 13 patients undergoing radical prostatectomy (Lu et al. 313 
2012). If this probe is effective in vivo, it could be combined with PET (positron emission 314 
tomography) scanning and be useful for discriminating between benign disease and cancer, and 315 
possibly for detecting micrometastases (Lu et al. 2012).  316 
 317 
Treatment with acylated ghrelin stimulates cell proliferation through the ERK1/2 pathway in the PC3 318 
and LNCaP prostate cancer cell lines (Jeffery et al., 2002, Yeh et al., 2005). Ghrelin may stimulate 319 
cell proliferation by acting through the GHSR1a, which is expressed in prostate cancer cell lines 320 
(Jeffery et al., 2002; Yeh et al., 2005), although it is also possible that ghrelin may act through the 321 
unidentified, widely hypothesised alternative ghrelin receptor (Chopin et al., 2012). We have 322 
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demonstrated that GOAT is expressed in prostate cancer cell lines (I Seim, P Jeffery, L Amorim, A 323 
Herington and L Chopin, 2012, unpublished observation), indicating that ghrelin may be acylated in 324 
these cells. The role of ghrelin in prostate cancer growth remains uncertain, however. A similar 325 
increase in cell proliferation in response to ghrelin treatment was seen in the PC3 cell line in another 326 
study using lower concentrations of ghrelin, while supraphysiological levels (1000 nM) inhibited 327 
proliferation in this study (Cassoni et al. 2004). Recently, a third laboratory demonstrated that ghrelin 328 
decreases proliferation and promotes apoptosis of PC3 cells (Diaz-Lezama et al. 2010). In this study, 329 
however, the investigators measured tritiated thymidine incorporation (DNA synthesis) in the last 6 330 
hours of a 72 hour ghrelin treatment, and it is unlikely that ghrelin would been intact at this point of 331 
the experiment. Ghrelin is unstable in culture, with a short half-life, with the octanoyl group 332 
(acylation) being rapidly lost and the peptide rapidly cleaved (De Vriese et al. 2004; Hosoda et al. 333 
2004). Contrasting observations have also been observed for the LNCaP and DU145 cell lines 334 
(Cassoni et al. 2004; Yeh et al. 2005). We propose that the observed discrepancies may arise from the 335 
use of different forms of the cell lines, the different types of assays used, and the handling and 336 
stability of the acylated ghrelin peptide.  337 
 338 
In2c-ghrelin is expressed in all normal testis samples examined, while it is expressed in a small 339 
number of testicular tumours. This correlates well with previous studies, which have shown that the 340 
ghrelin peptide is present in normal human testis (Gaytan et al. 2004; Ishikawa et al. 2007) and in a 341 
subset of testicular tumours (Gaytan et al. 2004). Employing a small number of normal samples, we 342 
also demonstrate that in2c-ghrelin is expressed in breast and ovarian tumours, but not in normal breast 343 
or ovary. The SKOV-3 ovarian cancer cell line expresses the in2c-ghrelin variant, but no expression 344 
was detected in the hOSE17.1 normal ovary-derived cell line. Ghrelin has previously been shown to 345 
be expressed in breast cancer and, as is the case for prostate cancer, studies from other laboratories 346 
report different responses in cell proliferation assays when cell lines are treated with exogenous 347 
ghrelin peptide (Cassoni et al. 2001; Jeffery et al. 2005).  348 
 349 
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The in2c-ghrelin isoform is expressed in a limited number of normal tissues (including the testis) and 350 
at higher levels in many tumours. In normal tissues, in2c-ghrelin expression was most abundantly 351 
expressed in lymph node tissue. Interestingly, the LNCaP cell line (Lymph Node Carcinoma of the 352 
Prostate), which demonstrated very high levels of in2c-ghrelin, is derived from a lymph node 353 
metastasis (Yu et al. 2009). Furthermore, in2c-ghrelin is expressed in peripheral blood leukocytes, 354 
indicating that it may play a role in immune regulation. Indeed, the ghrelin peptide has been shown to 355 
play an immunoregulatory role (Baatar et al. 2011). 356 
 357 
A number of other ghrelin isoforms have also been described previously (Seim et al. 2009; Seim et al. 358 
2011a), including exon 3-deleted preproghrelin (Jeffery et al. 2005; Yeh et al. 2005) and the intron 1-359 
retained transcript (originally termed in2-ghrelin, but renamed in1-ghrelin using the current ghrelin 360 
gene nomenclature) (Gahete et al. 2011; Gahete et al. 2010; Kineman et al. 2007). In1-ghrelin would 361 
encode a 117 amino acid polypeptide that includes the signal peptide of preproghrelin, the first 12 362 
amino acids of the 28 amino acid ghrelin peptide sequence and a novel 81 amino acid C-terminal 363 
peptide, but not obestatin (Gahete et al. 2011). In1-ghrelin is regulated in response to metabolic stress 364 
in mice (Kineman et al. 2007), and is down-regulated in particular brain regions in Alzheimer’s 365 
disease in humans (Gahete et al. 2010) and upregulated in breast cancer (Gahete et al., 2011).  366 
 367 
We speculate that the in2c-ghrelin variant is another example that illustrates an emerging theme 368 
where mRNA transcripts encode ghrelin, but not obestatin, as is the case for exon 3-deleted ghrelin 369 
and in1-ghrelin. Indeed, evidence is emerging that obestatin, the peptide derived from exon 3 of 370 
preproghrelin, may be a growth factor that could promote or inhibit cancer progression, depending on 371 
the cancer type (Pazos et al. 2009; Pazos et al. 2007; Volante et al. 2009). Similarly, putative 372 
obestatin-coding transcripts that lack the ghrelin coding region are also expressed in prostate cancer 373 
cell lines (Seim et al. 2007). These studies suggest that cells can regulate the production of ghrelin 374 
gene-derived peptides independently by means of alternative splicing and this could partly explain the 375 
observed lack of correlation between plasma ghrelin and obestatin peptide levels (Pemberton et al., 376 
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2002). One small study has reported that the ratio of acylated ghrelin to total ghrelin (acyl and desacyl 377 
ghrelin combined) in the circulation was higher in prostate cancer patients compared to subjects with 378 
benign prostatic hyperplasia (BPH) (Malendowicz et al. 2009). In contrast, obestatin was not elevated 379 
in these patients (Malendowicz et al. 2009). 380 
 381 
Insulin regulates a large number of genes (Hartmann et al. 2009; O'Brien and Granner 1996; Rome et 382 
al. 2003), and in this study, we have demonstrated that insulin increases the expression of in2c-ghrelin 383 
and in1-ghrelin in the LNCaP and 22Rv1 prostate cancer cell lines. Insulin treatment also upregulates 384 
ghrelin expression in mouse stomach oxyntic glands (which are the major site of ghrelin expression) 385 
(Toshinai et al. 2001), and in adipocytes (Gurriaran-Rodriguez et al. 2011). Conversely, insulin 386 
downregulates the expression of wild-type and in1-ghrelin mRNA in the mouse hypothalamus, where 387 
it has an effect on appetite regulation (Fick et al. 2009; Kineman et al. 2007). The regulation of 388 
ghrelin in cancer has yet to be established, and this is the first study to demonstrate regulation of 389 
ghrelin transcripts by insulin in cancer.  390 
 391 
Although in2c-ghrelin is insulin-regulated in the prostate, we failed to detect the in2c-ghrelin isoform 392 
in the pancreas itself, despite the fact that the wild-type ghrelin transcript and the ghrelin peptide are 393 
abundantly expressed in the endocrine pancreas and ghrelin appears to plays an important role in 394 
glucose homeostasis and insulin regulation (Granata et al. 2010). The importance of the ghrelin axis 395 
in the regulation of blood glucose was recently illustrated in a study of the ghrelin acylation enzyme, 396 
GOAT, knockout mouse, which is unable to produce acylated ghrelin. Under severe caloric restriction 397 
(60%), GOAT knockout mice are unable to maintain glucose homeostasis and die, however, animals 398 
can be rescued with the administration of acylated ghrelin or growth hormone (Zhao et al. 2010). This 399 
finding has been contradicted, however, by a comprehensive study using a range of mouse models, 400 
suggesting that the ghrelin axis may not play an important role in insulin regulation in response to 401 
caloric restriction (Yi et al. 2012).  402 
 403 
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Ghrelin has been linked directly with obesity given its clear role in appetite, energy balance and 404 
metabolic regulation, and ghrelin and GOAT are important targets for the treatment of obesity (Lim et 405 
al. 2011). In addition to being a risk factor for cancer, obesity is associated with metabolic syndrome, 406 
which is also typified by hyperinsulinaemia (Hammarsten and Peeker 2011). There is mounting 407 
evidence that elevated circulating insulin levels are positively associated with increased cancer risk 408 
and particularly with breast and prostate cancer (Amling 2005; Bao et al. 2011; Buschemeyer and 409 
Freedland 2007; Gunter et al. 2009; Hammarsten et al. 2010; Hammarsten and Hogstedt 2005; 410 
Hammarsten and Peeker 2011; Healy et al. 2010; LeRoith 2010; Ma et al. 2008; Suissa et al. 2011; 411 
Wilson 2011). Although there have been few studies at the cellular level, insulin appears to play a role 412 
in the progression of prostate cancer. Insulin stimulates cell proliferation in cultured breast and 413 
prostate cancer cell lines (Lann and LeRoith 2008; Pollak 2008), and promotes tumour progression by 414 
stimulating de novo steroidogenesis in prostate cancer (Lubik et al. 2011). Interestingly, diet-induced 415 
hyperinsulinaemia results in increased cell proliferation of LNCaP prostate cancer cell xenografts in 416 
mice (Venkateswaran et al. 2007). We show that in2c-ghrelin is expressed in the PC3 prostate cancer 417 
cell line, which is derived from a bone metastasis (Yu et al. 2009). Men with hyperinsulinaemia are 418 
more likely to develop bone metastases and progress faster to terminal, castrate-resistant prostate 419 
cancer (Lubik et al. 2011). While hyperinsulinaemia has been associated with prostate cancer 420 
progression, androgen deprivation therapy, the standard treatment for advanced prostate cancer, 421 
frequently gives rise to metabolic syndrome and insulin resistance, with hyperinsulinaemia, elevated 422 
fasting blood glucose and elevated C-reactive peptide (Aggarwal et al. 2011). As insulin treatment 423 
leads to increased ghrelin expression in the LNCaP prostate cancer cell line, this may also increase 424 
cell proliferation in prostate cancer.  425 
 426 
In conclusion, in the present study we have identified bona fide exons within intron 2 of the ghrelin 427 
gene locus (GHRL) and described a novel ghrelin isoform that, together with the recently described 428 
in1-ghrelin isoform, is upregulated by insulin in prostate cancer cell lines. In2c-ghrelin includes 429 
cryptic exon sequence and would result in the translation of an 83 amino acid preproghrelin isoform 430 
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that encodes ghrelin, but not obestatin. In2c-ghrelin is expressed in a range of tumour samples derived 431 
from the prostate, breast and ovary, but in a limited number of normal tissues, including lymph nodes, 432 
stomach and testis. Further studies are warranted to elucidate the role of the ghrelin gene products in 433 
normal physiology and in conditions associated with hyperinsulinaemia and in cancer. 434 
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Figures and Tables 685 
 686 
Table 1. Designations and sequences of RT-PCR primers. Annealing temperatures (Ta) of 687 
oligonucleotide primers employed in RT-PCR and the expected product sizes are shown.  688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
 704 
 705 
 706 
 707 
Primer 
name 
Primer sequence Ta (°C) Expected size 
(bp) 
In2c-ghrelin-
ORF-F 
CTTCCTGAGCCCTGAACACC 64 - 
In2c-ghrelin-
ORF-R 
TCAGCCTTAGCCTCTAATGGGA  - 
In2c-real-F AGAGGCATGAGAGTGCAAGTTC 64 131 
In2c-real-R GATGTCCTGAAGAAACTTCCCC   
In1-real-F TCTGGGCTTCAGTCTTCTCC 60 215 
In1-real-R GTTCATCCTCTGCCCCTTCT   
wt-real-F TCAGGGGTTCAGTACCAGCA 60 158 
wt-real-R CAAGCGAAAAGCCAGATGAC   
RPL32-F CCCCTTGTGAAGCCCAAGA 60 59 
RPL32-R GACTGGTGCCGGATGAACTT   
18S-F TTCGGAACTGAGGCCATGAT 60 151 
18S-R CGAACCTCCGACTTTCGTTCT   
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Figure legends 708 
 709 
Figure 1 Image depicting mRNA transcript architecture in the GHRL locus was obtained through the 710 
UCSC Genome Browser. Microarray analysis detected a 3.9-fold increase in the expression of novel 711 
exons (indicated in pink) in intron 2 of the ghrelin gene (GHRL). Wild-type-preproghrelin coding 712 
exons 2 to 4 are indicated in blue font, while the cryptic exons are indicated in red font. GenBank 713 
entries corresponding to the novel cryptic exons are indicated by a red box. 714 
 715 
Figure 2(A) Overview of the ghrelin locus showing the ghrelin gene, GHRL, with wild-type 716 
preproghrelin-coding exons in blue and the cryptic exons in intron 2 as red boxes (IIa, and the 5’ 717 
truncated exon IIb). Exons are represented as boxes and introns as horizontal lines. (B) Mapping of 718 
the novel cryptic exon ghrelin transcripts. The exon structure of amplicons is derived from the human 719 
testis and LNCaP cells. Exons are represented as boxes, and RT-PCR primers are indicated as arrows 720 
above exons. 721 
 722 
Figure 3 Multiple sequence alignment of wild-type preproghrelin and putative In2c-preproghrelin. 723 
Secretion signal peptides are shown in purple, ghrelin in blue, obestatin in red, and C-ghrelin is 724 
highlighted in grey. 725 
 726 
Figure 4 Relative expression of in2c-ghrelin in human tissues by quantitative real-time RT–PCR. 727 
Data were normalised to β-actin and are represented as fold changes relative to the expression in the 728 
adrenal gland (1.0).  729 
 730 
Figure 5 Relative expression of in2c-ghrelin in human cell lines using quantitative real-time RT-PCR. 731 
Data is represented as means and standard error of mean from two technical replicates of two 732 
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independent replicate experiments (n=2). The housekeeping gene, 18S ribosomal RNA, was used as a 733 
reference for normalisation. Data are represented as fold changes relative to expression of transcripts 734 
in the Beas-2B normal lung cell line (set at 1).  735 
 736 
Figure 6 Relative expression of in2c-ghrelin in cancer determined using real-time quantitative RT-737 
PCR. The labels in X-axis indicate the clinical status of the subjects (N denotes normal, Roman 738 
numerals indicate disease stages). Data represented as fold changes relative to the expression in a 739 
normal tissue sample (set at 1.0), or in the absence of expression in a normal tissue a tumour sample. 740 
(A) Testis (B) Prostate (C) Breast (D) Ovary. 741 
 742 
Figure 7 Real-time quantitative RT-PCR analysis of (A) in2-ghrelin and (B) in1-ghrelin gene 743 
expression in 22Rv1 and LNCaP prostate cancer cell lines in response to treatment with 10nM insulin 744 
over 48 hours. The housekeeping gene, Ribosomal protein L32, was used as a reference for 745 
normalisation. Data is represented as means and standard error of the mean with three technical 746 
replicates of three independent replicate experiments (n=3). *P<0.05 = significantly different from the 747 
vehicle-treated control (set at 1-fold) using Student’s t test. 748 
 749 
Supplementary Figure 1 Ethidium bromide-stained agarose electrophoresis gel of GHRL exon 1 to II 750 
(non-quantitative) RT-PCR amplicons in the LNCaP prostate cancer cell line, testis and pancreas. 751 
NTC = no template control (water). M = 100 bp DNA molecular weight marker (New England 752 
Biolabs). 753 
 754 
Supplementary Figure 2 (A) Overview of In2c-ghrelin real-time, quantitative RT-PCR assay design 755 
where the reverse PCR primer spans the exon II-exon 3 junction to eliminate gDNA and pre-mRNA 756 
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amplification and amplify In2c-ghrelin transcripts only. (B) Agarose gel separation of quantitative 757 
RT-PCR products generated by interrogating the pancreas and testis with the in2c-ghrelin primers. (C) 758 
Dissociation curves of quantitative RT-PCR products (annealing at 64°C) generated from the 759 
pancreas and testis using the in2c-ghrelin primers. 760 
 761 
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Figure 1 Image depicting mRNA transcript architecture in the GHRL locus was obtained through the UCSC 
Genome Browser. Microarray analysis detected a 3.9-fold increase in the expression of novel exons 
(indicated in pink) in intron 2 of the ghrelin gene (GHRL). Wild-type-preproghrelin coding exons 2 to 4 are 
indicated in blue font, while the cryptic exons are indicated in red font. GenBank entries corresponding to 
the novel cryptic exons are indicated by a red box.  
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Figure 2(A) Overview of the ghrelin locus showing the ghrelin gene, GHRL, with wild-type preproghrelin-
coding exons in blue and the cryptic exons in intron 2 as red boxes (IIa, and the 5’ truncated exon IIb). 
Exons are represented as boxes and introns as horizontal lines. (B) Mapping of the novel cryptic exon 
ghrelin transcripts. The exon structure of amplicons is derived from the human testis and LNCaP cells. Exons 
are represented as boxes, and RT-PCR primers are indicated as arrows above exons.  
1057x472mm (72 x 72 DPI)  
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Figure 3 Multiple sequence alignment of wild-type preproghrelin and putative In2c-preproghrelin. Secretion 
signal peptides are shown in purple, ghrelin in blue, obestatin in red, and C-ghrelin is highlighted in grey.  
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Figure 4 Relative expression of in2c-ghrelin in human tissues by quantitative real-time RT–PCR. Data were 
normalised to β-actin and are represented as fold changes relative to the expression in the adrenal gland 
(1.0).  
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Figure 5 Relative expression of in2c-ghrelin in human cell lines using quantitative real-time RT-PCR. Data is 
represented as means and standard error of mean from two technical replicates of two independent replicate 
experiments (n=2). The housekeeping gene, 18S ribosomal RNA, was used as a reference for normalisation. 
Data are represented as fold changes relative to expression of transcripts in the Beas-2B normal lung cell 
line (set at 1).  
793x793mm (72 x 72 DPI)  
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Figure 6 Relative expression of in2c-ghrelin in cancer determined using real-time quantitative RT-PCR. The 
labels in X-axis indicate the clinical status of the subjects (N denotes normal, Roman numerals indicate 
disease stages). Data represented as fold changes relative to the expression in a normal tissue sample (set 
at 1.0), or in the absence of expression in a normal tissue a tumour sample. (A) Testis (B) Prostate (C) 
Breast (D) Ovary.  
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Figure 7 Real-time quantitative RT-PCR analysis of (A) in2-ghrelin and (B) in1-ghrelin gene expression in 
22Rv1 and LNCaP prostate cancer cell lines in response to treatment with 10nM insulin over 48 hours. The 
housekeeping gene, Ribosomal protein L32, was used as a reference for normalisation. Data is represented 
as means and standard error of the mean with three technical replicates of three independent replicate 
experiments (n=3). *P<0.05 = significantly different from the vehicle-treated control (set at 1-fold) using 
Student’s t test.  
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Table 1. Designations and sequences of RT-PCR primers. Annealing temperatures (Ta) of 
oligonucleotide primers employed in RT-PCR and the expected product sizes are shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer 
name 
Primer sequence Ta (°C) Expected size 
(bp) 
In2c-ghrelin-
ORF-F 
CTTCCTGAGCCCTGAACACC 64 - 
In2c-ghrelin-
ORF-R 
TCAGCCTTAGCCTCTAATGGGA  - 
In2c-real-F AGAGGCATGAGAGTGCAAGTTC 64 131 
In2c-real-R GATGTCCTGAAGAAACTTCCCC   
In1-real-F TCTGGGCTTCAGTCTTCTCC 60 215 
In1-real-R GTTCATCCTCTGCCCCTTCT   
wt-real-F TCAGGGGTTCAGTACCAGCA 60 158 
wt-real-R CAAGCGAAAAGCCAGATGAC   
RPL32-F CCCCTTGTGAAGCCCAAGA 60 59 
RPL32-R GACTGGTGCCGGATGAACTT   
18S-F TTCGGAACTGAGGCCATGAT 60 151 
18S-R CGAACCTCCGACTTTCGTTCT   
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